Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Edgewise Therapeutics Inc
(NQ:
EWTX
)
19.22
+0.40 (+2.13%)
Streaming Delayed Price
Updated: 12:22 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Edgewise Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday
April 25, 2023
U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
April 19, 2023
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the...
Via
Benzinga
Edgewise Therapeutics Announces Journal of Clinical Investigation Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models of Duchenne Muscular Dystrophy (DMD)
March 30, 2023
From
Edgewise Therapeutics
Via
Business Wire
Recap: Edgewise Therapeutics Q2 Earnings
August 04, 2022
Edgewise Therapeutics (NASDAQ:EWTX) reported its Q2 earnings results on Thursday, August 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Top 5 Health Care Stocks That Preparing To Pump This Quarter
March 29, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023
March 21, 2023
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific Conference
March 14, 2023
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors
March 06, 2023
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Present at the Cowen 43rd Annual Health Care Conference on March 8, 2023
March 01, 2023
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Announces Upcoming Presentation at the American College of Cardiology's 72nd Annual Scientific Session Together with World Congress of Cardiology
February 28, 2023
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
February 23, 2023
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Present at the SVB Securities Global Biopharma Conference on February 14, 2023
February 07, 2023
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
January 04, 2023
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Showcase Novel Cardiac Program at Virtual Investor Event on Tuesday, January 3, 2023
December 21, 2022
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer
December 20, 2022
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Present at Upcoming Investor Conferences
November 09, 2022
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Reports Third Quarter 2022 Financial Results
November 03, 2022
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
October 27, 2022
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Announces Positive 6-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
October 13, 2022
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 27th International Hybrid Annual Congress of the World Muscle Society
October 06, 2022
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 16, 2022
From
Edgewise Therapeutics, Inc.
Via
Business Wire
Why ZW Data Action Technologies Jumped 37%; Here Are 71 Biggest Movers From Yesterday
September 16, 2022
Gainers
Via
Benzinga
Edgewise Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
September 13, 2022
From
Edgewise Therapeutics
Via
Business Wire
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
September 14, 2022
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX...
Via
Benzinga
Edgewise Therapeutics Announces Proposed Offering of Common Stock
September 13, 2022
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
September 11, 2022
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
September 07, 2022
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Reports Second Quarter 2022 Financial Results
August 04, 2022
From
Edgewise Therapeutics, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
August 25, 2022
Upgrades
Via
Benzinga
Edgewise Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on August 9
August 03, 2022
From
Edgewise Therapeutics
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.